Undergraduates Michael Morikado, Ryan Storgard, and Matthew Lin represented the Kuhn-Hicks Lab at the 2018 #Undergraduate#Symposium for Scholarly and Creative Work. They are pictured with their liquid biopsy #research and mentor, Paymaneh Malihi. Great job, guys!
The Breast Cancer Research Foundation has recently joined the Blood Profiling Atlas in Cancer (BloodPAC) and, through its Pink Initiative, is supporting the national liquid biopsy initiative. This new method of tracking, managing, and understanding breast cancer has the opportunity to making a very real difference in how its patients are cared for.
Congratulations to Ph.D. Candidate Lisa Welter on being chosen to receive an American Association for Cancer Research (AACR) Scholar-in-Training Award! Her abstract entitled "Characterization of disease evolution in sequential sampled metastatic breast cancer using liquid biopsy" was selected from a large candidate pool and will support her attending the 2018 AACR Annual Meeting.
The review “Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation” by Keating and colleagues is now published in Clin Transl Sci. In this article, the challenges encountered with newly evolving high-content measurement systems are illustrated with examples of two platforms: our High Definition Single Cell Analysis (HD-SCA) workflow, optimized for identifying and characterizing rare cells in liquid biopsy samples, and the MultiOmyx Immunofluorescence (MxIF), for enabling “hyperplexed” measurements of proteins and nucleic acids in single cells or in tissues.
“The platforms profiled here are examples of instruments that translate high-content information out of the research laboratory to the clinical research setting for characterization and monitoring of single cells in tissue or blood. They go beyond enumeration of assay end points to enable profiling of heterogeneous cell populations. As such, the systems could be exploited in the drug development and clinical arenas not only for in vitro evaluations guiding clinical decisions, but also ex vivo studies, such as assessing target activity, probing for clinically relevant targets, and characterizing cancer cell and tumor heterogeneity.”
The study “Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry” by E. Gerdtsson and colleagues, published in January by Convergent Science Physical Oncology, established the proof of concept for the metal-detection technique, which allows scientists to see circulating and disseminated tumor cells at a molecular level in a way not possible before. The new approach of using metal-tagged antibodies and a laser ablation system, coupled with a mass spectrometer, gives scientists the ability to track 35 different metal labels simultaneously. Because of proof-of-concept studies like this, the technique is now an official product of Fluidigm and is available for researchers worldwide.